DK3692015T3 - Hidtil ukendte glutaminantagonister og anvendelser deraf - Google Patents

Hidtil ukendte glutaminantagonister og anvendelser deraf Download PDF

Info

Publication number
DK3692015T3
DK3692015T3 DK18864999.0T DK18864999T DK3692015T3 DK 3692015 T3 DK3692015 T3 DK 3692015T3 DK 18864999 T DK18864999 T DK 18864999T DK 3692015 T3 DK3692015 T3 DK 3692015T3
Authority
DK
Denmark
Prior art keywords
previously unknown
glutamine antagonists
antagonists
glutamine
unknown
Prior art date
Application number
DK18864999.0T
Other languages
English (en)
Inventor
Barbara Slusher
Pavel Majer
Lukas Tenora
Katerina Novotna
Jesse Alt
Rana Rais
Original Assignee
Univ Johns Hopkins
Ustav Organicke Chemie A Biochemie Av Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Ustav Organicke Chemie A Biochemie Av Cr V V I filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3692015T3 publication Critical patent/DK3692015T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C245/18—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18864999.0T 2017-10-06 2018-10-05 Hidtil ukendte glutaminantagonister og anvendelser deraf DK3692015T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569118P 2017-10-06 2017-10-06
US201862728214P 2018-09-07 2018-09-07
PCT/US2018/054581 WO2019071110A1 (en) 2017-10-06 2018-10-05 NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK3692015T3 true DK3692015T3 (da) 2022-11-21

Family

ID=65994832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18864999.0T DK3692015T3 (da) 2017-10-06 2018-10-05 Hidtil ukendte glutaminantagonister og anvendelser deraf

Country Status (7)

Country Link
US (1) US12195419B2 (da)
EP (1) EP3692015B1 (da)
JP (1) JP7358342B2 (da)
CN (1) CN111566083A (da)
DK (1) DK3692015T3 (da)
ES (1) ES2930258T3 (da)
WO (1) WO2019071110A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11185534B2 (en) 2017-02-01 2021-11-30 The Johns Hopkins University Prodrugs of glutamine analogs
US20210177841A1 (en) * 2017-11-03 2021-06-17 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
MX2021008546A (es) * 2019-01-18 2021-11-12 Dracen Pharmaceuticals Inc Terapia combinada con un profarmaco de 6-diazo-5-oxo-l-norleucina (don) y un inhibidor de puntos de control inmunologicos.
WO2020167831A1 (en) 2019-02-11 2020-08-20 Dracen Pharmaceuticals, Inc. Method of preparing a don prodrug from l-glutamic acid
WO2020167829A1 (en) * 2019-02-11 2020-08-20 Dracen Pharmaceuticals, Inc. Method of preparing a don prodrug from l-pyroglutamic acid
WO2020190866A1 (en) * 2019-03-18 2020-09-24 Alteron Therapeutics, Llc Modulators of tdp-43
WO2021239049A1 (en) * 2020-05-27 2021-12-02 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022022612A1 (en) * 2020-07-29 2022-02-03 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022078462A1 (en) * 2020-10-15 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
EP4229029B1 (en) 2020-10-15 2026-02-25 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
JP2025078888A (ja) * 2022-01-28 2025-05-21 国立大学法人富山大学 グルタミナーゼ阻害剤
TW202404938A (zh) * 2022-04-21 2024-02-01 大陸商北京加科思新藥研發有限公司 麩醯胺酸拮抗劑的多晶型及其用途
JP2025540593A (ja) * 2022-11-02 2025-12-16 ザ・ジョンズ・ホプキンス・ユニバーシティ 優先的な腫瘍への送達を伴うアゾトマイシンプロドラッグ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158976A (en) 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
WO2007001395A2 (en) 2004-10-04 2007-01-04 University Of South Carolina Prevention and treatment of influenza with glutamine antagonist agents
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2009029729A1 (en) 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
HRP20231163T1 (hr) 2015-07-31 2024-03-15 The Johns Hopkins University Prolijekovi glutaminskih analoga
EP3328376A4 (en) * 2015-07-31 2019-03-13 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
WO2017023791A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Glutamine antagonists for the treatment of cognitive deficits
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
US11185534B2 (en) 2017-02-01 2021-11-30 The Johns Hopkins University Prodrugs of glutamine analogs

Also Published As

Publication number Publication date
US20230009398A1 (en) 2023-01-12
CN111566083A (zh) 2020-08-21
ES2930258T3 (es) 2022-12-09
EP3692015A1 (en) 2020-08-12
WO2019071110A1 (en) 2019-04-11
JP2020536867A (ja) 2020-12-17
EP3692015B1 (en) 2022-08-24
EP3692015A4 (en) 2021-06-30
JP7358342B2 (ja) 2023-10-10
US12195419B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
DK3692015T3 (da) Hidtil ukendte glutaminantagonister og anvendelser deraf
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3609888T3 (da) Farnesoid x-receptor-agonister og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
DK3551221T3 (da) Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf